PandemicPreparedness

31 March 2022: Results from a clinical trial conducted in Brazil and published by The New England Journal of Medicine found no evidence of ivermectin treatment reducing the likelihood of being admitted to the hospital due to COVID-19 or shortening the time to recover from the disease.

30 June 2021: A meta-analysis published in Clinical Infectious Diseases has concluded that ivermectin “is not a viable option to treat COVID-19 patients.” Ten randomised control trials were included in the analysis. The researchers found the ivermectin didn’t reduce mortality, length of hospital stay or clearing virus compared to placebo or standard of care treatment. Nor did it have any effect on adverse events.

18 January 2021: The National Institutes of Health which is part of the U.S. Department of Health and Human Services, released ‘The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Ivermectin for the Treatment of COVID-19’. The recommendation “The COVID-19 Treatment Guidelines Panel (the Panel) has determined that currently there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin for the treatment of COVID-19.”